Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE37.9950
- TODAY'S CHANGE (%)-0.5850 (-1.5163%)
- Bid / Lots37.9200/ 4
- Ask / Lots38.0700/ 1
- Open / Previous Close38.2600 / 38.5800
- Day Range
- 52 Week Range
- Volume84,921
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 13993 | 38.34 |
| 09:34 ET | 900 | 38.595 |
| 09:36 ET | 6961 | 38.4 |
| 09:38 ET | 1710 | 37.985 |
| 09:41 ET | 100 | 37.95 |
| 09:43 ET | 200 | 38.15 |
| 09:45 ET | 100 | 37.89 |
| 09:50 ET | 434 | 37.86 |
| 09:52 ET | 100 | 37.77 |
| 09:56 ET | 200 | 37.81 |
| 09:57 ET | 100 | 37.87 |
| 09:59 ET | 100 | 37.83 |
| 10:01 ET | 400 | 37.8 |
| 10:03 ET | 543 | 37.96 |
| 10:06 ET | 200 | 37.81 |
| 10:08 ET | 100 | 37.8 |
| 10:10 ET | 200 | 37.78 |
| 10:12 ET | 755 | 37.665 |
| 10:14 ET | 100 | 37.615 |
| 10:17 ET | 700 | 37.53 |
| 10:21 ET | 300 | 37.59 |
| 10:24 ET | 1000 | 38.12 |
| 10:30 ET | 100 | 38.06 |
| 10:32 ET | 200 | 37.995 |
| 10:33 ET | 100 | 37.855 |
| 10:37 ET | 100 | 37.85 |
| 10:39 ET | 200 | 37.83 |
| 10:42 ET | 200 | 37.89 |
| 10:44 ET | 636 | 37.795 |
| 10:46 ET | 2200 | 38.19 |
| 10:50 ET | 200 | 38.29 |
| 10:51 ET | 100 | 38.255 |
| 10:53 ET | 400 | 38.24 |
| 10:55 ET | 150 | 38.21 |
| 10:57 ET | 100 | 38.1 |
| 11:00 ET | 100 | 38.14 |
| 11:04 ET | 300 | 38.1 |
| 11:06 ET | 100 | 38.2 |
| 11:08 ET | 2488 | 38.24 |
| 11:09 ET | 100 | 38.22 |
| 11:11 ET | 300 | 38.31 |
| 11:13 ET | 750 | 38.16 |
| 11:15 ET | 633 | 38.25 |
| 11:18 ET | 100 | 38.26 |
| 11:20 ET | 300 | 38.26 |
| 11:22 ET | 100 | 38.29 |
| 11:24 ET | 387 | 38.18 |
| 11:26 ET | 200 | 38.24 |
| 11:27 ET | 550 | 38.145 |
| 11:29 ET | 300 | 38.125 |
| 11:31 ET | 614 | 38.21 |
| 11:33 ET | 150 | 38.37 |
| 11:36 ET | 943 | 38.22 |
| 11:38 ET | 400 | 38.37 |
| 11:40 ET | 400 | 38.45 |
| 11:42 ET | 200 | 38.51 |
| 11:45 ET | 650 | 38.49 |
| 11:49 ET | 450 | 38.39 |
| 11:51 ET | 400 | 38.43 |
| 11:54 ET | 300 | 38.39 |
| 11:56 ET | 200 | 38.4575 |
| 11:58 ET | 250 | 38.46 |
| 12:00 ET | 577 | 38.44 |
| 12:02 ET | 222 | 38.435 |
| 12:03 ET | 100 | 38.355 |
| 12:05 ET | 100 | 38.26 |
| 12:07 ET | 200 | 38.2975 |
| 12:09 ET | 200 | 38.35 |
| 12:12 ET | 100 | 38.325 |
| 12:14 ET | 400 | 38.16 |
| 12:16 ET | 300 | 38.19 |
| 12:18 ET | 500 | 38.12 |
| 12:20 ET | 300 | 38.01 |
| 12:21 ET | 400 | 38.14 |
| 12:23 ET | 200 | 38.17 |
| 12:25 ET | 100 | 38.07 |
| 12:27 ET | 200 | 38.17 |
| 12:30 ET | 100 | 38.16 |
| 12:32 ET | 700 | 38.0201 |
| 12:34 ET | 600 | 38.195 |
| 12:38 ET | 300 | 38.21 |
| 12:39 ET | 200 | 38.23 |
| 12:43 ET | 400 | 38.065 |
| 12:45 ET | 400 | 37.995 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 2.3B | -18.6x | --- |
Iovance Biotherapeutics Inc | 2.3B | -4.3x | --- |
Structure Therapeutics Inc | 2.3B | -16.5x | --- |
CG Oncology Inc | 2.1B | -27.8x | --- |
Janux Therapeutics Inc | 2.2B | -32.8x | --- |
Vera Therapeutics Inc | 2.0B | -17.0x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark McKenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.04 |
Book Value | $7.86 |
P/E Ratio | -18.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
